Searchable abstracts of presentations at key conferences in endocrinology

ea0015p176 | Endocrine tumours and neoplasia | SFEBES2008

A novel mechanism of thyroid tumorigenesis based on inactivation of p53 by the PTTG-binding factor PBF

Read Martin , Turnell Andy , Kim Dae , Watkins Rachel , Smith Vicki , Fong Jim , Watkinson John , Boelaert Kristien , Franklyn Jayne , McCabe Chris

The pituitary tumor transforming gene binding factor (PBF) is a poorly characterised gene that is over-expressed in pituitary and thyroid tumours. Recently, we showed that subcutaneous expression of PBF elicits tumours in nude mice, and expression correlates with thyroid tumour recurrence in man. Given the established role of ionising radiation in thyroid tumourigenesis, we have now investigated the relationship between PBF and the tumour suppressor gene p53, a central compone...

ea0059p224 | Thyroid | SFEBES2018

Identification of novel sodium iodide symporter (NIS) interactors which modulate radioiodine uptake

Fletcher Alice , Poole Vikki , Thornton Caitlin , Baker Kate , Thompson Rebecca , Nieto Hannah , Alshahrani Mohammed , Read Martin , Turnell Andy , Boelaert Kristien , Smith Vicki , McCabe Chris

Patients termed to have radioiodine-refractory differentiated thyroid cancer (RR-DTC) cannot accumulate sufficient radioiodine for a therapeutic response due to sodium iodide symporter (NIS) dysregulation via diminished expression and/or altered plasma membrane (PM) localisation. Currently, the regulation of NIS localisation remains poorly defined and despite protein-protein interactions being well-described to modulate trafficking events, the NIS interactome is limited. Previ...

ea0038p148 | Neoplasia, cancer and late effects | SFEBES2015

PTTG is phosphorylated at residue T60 and regulates p53 stability, in conjunction with PBF, in head and neck cancer

Modasia Bhavika , Read Martin L , Smith Vicki E , Turnell Andy S , Rae Peter C , Watkins Rachel J , Imruetaicharoenchoke Waraporn , Poole Vikki L , Mehanna Hisham , McCabe Chris J

PTTG is a multifunctional proto-oncogene, overexpressed in thyroid, pituitary and other endocrine cancers. PTTG is also implicated in the pathogenesis of head and neck cancer, where high PTTG expression independently correlates with advanced tumour stage and reduced disease-free survival. Recently, abrogation of residue threonine-60 (T60) has been associated with altered PTTG half-life, chromosomal instability and cell invasion. We therefore generated a phospho-specific antibo...